Skip to content
Clinical Trials – home

Institutul De Psihiatrie Socola Lasi

Verified siteinfo

Romania Soseaua Bucium 36, 700282 Iasi, Romania

  • 15 trials recruiting
  • Schizophrenia · Bipolar I disorder · Dementia Alzheimer's type
  • Adults and children

About Specializations

Institutul De Psihiatrie Socola Lasi in Iasi, Romania specialises in clinical trials of conditions such as Schizophrenia, Bipolar I disorder, Dementia Alzheimer's type, Mania, and other specialisations. This site conducts important research.

Main research areas of the site

Psychiatry and Psychology and Mental Disorders

At Institutul De Psihiatrie Socola Lasi in Iasi, this research area focuses on treatments for schizophrenia, bipolar I disorder, and major depressive disorder, with additional work in behavioral disciplines and mental health care. The trials are designed to test new therapies, improve symptom control, and support longer-term management for people living with complex psychiatric conditions.

  • Studies in schizophrenia include research on acute psychosis, inpatient care, and adolescent patients, with the goal of improving symptom relief and overall functioning.
  • Trials in bipolar I disorder examine approaches for manic episodes and mixed features, aiming to reduce severity and strengthen treatment effectiveness.
  • Research in major depressive disorder explores options for depressive symptoms, anhedonia, and insomnia, including efforts to prevent relapse and improve daily well-being.

Overall, the site contributes to clinical research that seeks better psychiatric treatments for both acute symptoms and longer-term outcomes.

Nervous System Diseases

The site also supports clinical studies linked to nervous system diseases, especially conditions where brain function and behavior are affected, such as Alzheimer’s disease and related psychotic or agitated states. These trials aim to evaluate new treatment options that may ease symptoms, improve cognition, and enhance quality of life for patients and caregivers.

  • Research in Alzheimer’s disease includes studies of agitation, hallucinations, and delusions, with a focus on better symptom management.
  • Some trials address cognitive impairment and global functioning, looking for ways to support thinking skills in people with mild to moderate disease.
  • The research also examines behavioral symptoms that overlap with psychiatric care, reflecting the close link between brain disorders and mental health.

This work shows a strong interest in therapies that target both neurological and psychiatric symptoms in older adults.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Soseaua Bucium 36700282 IasiRomania
Recruiting now
15 trials
Conditions studied
10
Partner status
Verified site

More sites in IasiRomania

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

20 clinical trials

Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer's disease patients: Long-term safety evaluation

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Efficacy, Safety, and Tolerability of NBI-1065890 in Adults with Tardive Dyskinesia

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Sponsor:Neurocrine Biosciences Inc.

Schizophrenia

Recruiting

Efficacy and safety of roluperidone versus drug combination in adults with schizophrenia with negative symptoms

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Aripiprazole

Schizophrenia+1

Recruiting

Long‑Term Safety and Tolerability of KarXT in Adolescents with Schizophrenia and of KarXT + KarX‑EC in Children and Adolescents with Autism‑Related Irritability

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Schizophrenia

Recruiting

A study to evaluate the efficacy and safety of trospium chloride and xanomeline tartrate for the treatment of schizophrenia in adolescents aged 13 to 17 years

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Schizophrenia

Recruiting

A study to evaluate the effectiveness and safety of NBI-1117570 in adults with schizophrenia who require hospital treatment.

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:HTL0022537
  • Sponsor:Neurocrine Biosciences Inc.

Schizophrenia

Recruiting

A Study Testing Brexpiprazole Given Once Weekly to Treat Sudden Worsening of Symptoms in Patients with Schizophrenia

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Brexpiprazole
  • Sponsor:Otsuka Pharmaceutical Co. Ltd.

Bipolar I disorder+1

Recruiting

A study testing xanomeline tartrate and trospium chloride added to current treatment for adults with bipolar I disorder experiencing mania

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Schizophrenia

Recruiting

Long-Term Safety Study of Direclidine in Adults with Schizophrenia

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Direclidine
  • Sponsor:Neurocrine Biosciences Inc.

Schizophrenia

Recruiting

A study testing direclidine compared to placebo in adults with schizophrenia who need hospital care

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Direclidine
  • Sponsor:Neurocrine Biosciences Inc.

A Study of fesoterodine and 5-[(1R,5R)-3-Azabicyclo[3.

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Fesoterodine
  • Sponsor:Maplight Therapeutics Inc.

Study of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer's disease

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.